Orforglipron 2212020-52-3

Orforglipron Base(CAS 2212020-52-3)

   In pharmaceutical R&D and manufacturing, Orforglipron base (CAS: 2212020-52-3) serves as an intermediate/precursor for Orforglipron hemicalcium hydrate (CAS: 3008544-96-2). The hemicalcium hydrate form typically offers superior solubility and bioavailability, which is why Eli Lilly ultimately selected it as the commercial API form. This conversion also represents a critical process step in the synthesis and purification of Orforglipron.

  The core objective of this synthetic route is to achieve polymorphism control and enhance the stability and purity of the final product.

Step 1: Synthesis of the Free Base

Chemists first construct the core scaffold of Orforglipron through complex multi-step reactions (typically involving various protecting group strategies and coupling reagents such as HATU). This yields Orforglipron base (CAS: 2212020-52-3), which at this stage is generally amorphous or in a primary crystalline form requiring further purification.

Step 2: Salt Formation and Crystallization

To obtain a stable physical form suitable for drug formulation, the process guides the free base Orforglipron to react with a calcium salt (e.g., calcium chloride) in specific solvent systems. By precisely controlling the water content, the process yields Orforglipron hemicalcium hydrate (CAS: 3008544-96-2) with a stable crystal structure and controlled quality.